Deepak Sampath is graduated from Washington University in St. Louis, Graduate School of Arts and Sciences earning a PhD in Molecular Cell Biology and Biomedical Sciences. Following a post-doctoral fellowship at Wyeth Research, Dr. Sampath joined the Department of Oncology at Wyeth Pharmaceuticals as Senior Scientist focusing on the discovery of orally bioavailable taxanes. Presently, Dr. Sampath is a Principal Scientist at Genentech in the Department of Translational Oncology and his lab focuses on the molecular and in vivo pharmacology of drugs that target the PI3K/Akt and BCL-2 apoptotic pathways in solid and hematological cancers. Deepak Sampath is graduated from Washington University in St. Louis, Graduate School of Arts and Sciences earning a PhD in Molecular Cell Biology and Biomedical Sciences. Following a post-doctoral fellowship at Wyeth Research, Dr. Sampath joined the Department of Oncology at Wyeth Pharmaceuticals as Senior Scientist focusing on the discovery of orally bioavailable taxanes. Presently, Dr. Sampath is a Principal Scientist at Genentech in the Department of Translational Oncology and his lab focuses on the molecular and in vivo pharmacology of drugs that target the PI3K/Akt and BCL-2 apoptotic pathways in solid and hematological cancers.

Obstetrics and Gynaecology